Cytokines

Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid
Nicole Yager, Suzanne Cole, Alicia Lledo Lara, Ash Maroof, Frank Penkava, Julian C Knight, Paul Bowness, Hussein Al-Mossawi

Annals of the Rheumatic Diseases Jul 2021, annrheumdis-2021-220280; DOI: 10.1136/annrheumdis-2021-220280
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan
Yohei Kirino, Kaoru Takase-Minegishi, Naomi Tsuchida, Lisa Hirahara, Yosuke Kunishita, Ryusuke Yoshimi, Hideaki Nakajima

Annals of the Rheumatic Diseases Jun 2021, annrheumdis-2021-220876; DOI: 10.1136/annrheumdis-2021-220876
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo

Annals of the Rheumatic Diseases Jul 2021, 80 (7) 865-875; DOI: 10.1136/annrheumdis-2020-219012
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
Daniel J Wallace, Florence Figueras, William A Wegener, David M Goldenberg

Annals of the Rheumatic Diseases Jul 2021, 80 (7) 954-955; DOI: 10.1136/annrheumdis-2020-219803
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
Oleg Melikhov, Tatiana Kruglova, Karine Lytkina, Georgy Melkonyan, Elena Prokhorovich, Gleb Putsman, Grigory Rodoman, Arkady Vertkin, Alena Zagrebneva, Justin Stebbing

Annals of the Rheumatic Diseases Jun 2021, annrheumdis-2021-220049; DOI: 10.1136/annrheumdis-2021-220049
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, Alice Gottlieb

Annals of the Rheumatic Diseases May 2021, annrheumdis-2020-219014; DOI: 10.1136/annrheumdis-2020-219014
Response to: ‘COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study’ by Cuceoglu et al
Carlo Salvarani, Gianluigi Bajocchi, Pamela Mancuso, Elena Galli, Francesco Muratore, Paolo Giorgi Rossi

Annals of the Rheumatic Diseases Jun 2021, 80 (6) e96; DOI: 10.1136/annrheumdis-2020-218364
TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors
Cecilia Ansalone, John Cole, Sabarinadh Chilaka, Flavia Sunzini, Shatakshi Sood, Jamie Robertson, Stefan Siebert, Iain B McInnes, Carl S Goodyear

Annals of the Rheumatic Diseases Jun 2021, 80 (6) 748-757; DOI: 10.1136/annrheumdis-2020-219262
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2021-220411; DOI: 10.1136/annrheumdis-2021-220411
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H Pillinger

Annals of the Rheumatic Diseases May 2021, 80 (5) 550-557; DOI: 10.1136/annrheumdis-2020-219174

Main menu

Cytokines

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cytokines

Pages